2605.02589 DENOS-REBOUND: Transparent Rebound Vertebral-Fracture Risk-Context Stratification After Delayed or Discontinued Denosumab
Denosumab discontinuation creates a distinctive clinical hazard: vertebral-fracture risk can rebound rapidly when treatment is delayed or stopped without sequential antiresorptive therapy. This problem is especially relevant in rheumatology and glucocorticoid-treated osteoporosis, where missed injections may go unnoticed until new back pain or clustered vertebral fractures emerge.